ZNTL · Zentalis Pharmaceuticals, Inc.

Zentalis Pharmaceuticals reported its first quarter 2026 financial results, highlighting significant clinical progress for its lead candidate azenosertib. The company selected 400mg QD 5:2 as the pivotal monotherapy dose for Cyclin E1-positive platinum-resistant ovarian cancer (PROC) based on a pre-specified interim analysis from DENALI Part 2a, which showed a meaningful response rate differentiation and comparable safety profiles. Concurrently, the first patient was dosed in the ASPENOVA Phase 3 confirmatory trial, designed to support full approval. Management emphasized that the DENALI Part 2 topline readout is expected by year-end 2026, with potential to support an accelerated approval pathway. Financially, the company ended the quarter with $211.8 million in cash, cash equivalents and marketable securities, providing runway into late 2027. R&D expenses increased to $28.7 million from $27.2 million in the prior year quarter, driven by clinical and drug manufacturing costs for the DENALI and ASPENOVA trials. Total operating expenses decreased to $37.9 million from $45.6 million, partly due to a non-recurring $7.8 million restructuring charge in the prior year. The company also initiated pre-commercial launch preparedness activities, including adding commercial capabilities and scaling manufacturing. The analyst consensus context shows recent EPS misses, but the company's clinical milestones and cash position are key investor focus points.